GoDubai
  
  
  
  
Citylife > Press Release
  Home Contact us Add to Favourites
Most Recent Postings
More Press Releses
Featured Sections

Event Finder
A daily roundup of exhibitions, promotions and other events in Dubai and the rest of the Emirates.
Submit an Event
Latest Dubai Press Releases >>

 
  Share
  • The pharmaceutical leader conducted an industry-first head-to-head study of two biologic therapies commonly used to treat the illness: vedolizumab and adalimumab
  • Vedolizumab was found to be superior in achieving clinical remission and mucosal healing at week 52
  • Study focused on patients with moderately to severely active ulcerative colitis  
Dubai, UAE, March 11, 2019:   Global biopharmaceutical company Takeda today announced the results of its pioneering VARSITY study into the effectiveness of two common therapies used to treat Ulcerative Colitis. Shared at the 14th Congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen Denmark, the findings showed that the use of vedolizumab – a gut-selective biologic treatment, was more effective overall at tackling the illness when compared to adalimumab– a common anti-tumor therapy.
 
Specifically, the study found that by week 52 of treatment among patients with moderate to severely active ulcerative colitis, 31.3 percent of those receiving vedolizumab intravenously experienced clinical remission*, compared to 22.5 percent of patients receiving adalimumab via injection at week 52. In addition, 39.7 percent of patients treated with vedolizumab recorded mucosal healing** - a slowing of the disease's progression, compared to 27.7 percent of those receiving adalimumab.
 
A non-statistically significant difference in favor of adalimumab was seen among patients who stopped taking oral corticosteroids - steroid hormones that are usually produced in the adrenal gland and were in clinical remission*** at week 52. Meanwhile, although the study was not conducted to compare the safety of the two treatments, patients treated with vedolizumab had a lower rate (62.7 percent) of adverse effects over 52 weeks compared to patients receiving adalimumab treatment (69.2 percent). Those treated with vedolizumab recorded a lower rate of infection (33.5 percent) compared to patients treated with adalimumab (43.5 percent). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).
 
“The VARSITY study addresses critical questions concerning the selection of biologic therapy in ulcerative colitis. The goal of treatment of this disease is to achieve clinical remission and mucosal healing, and these results clearly highlight the benefits seen with vedolizumab versus adalimumab towards these important outcomes.” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of both the Dr. Henry D. Janowitz Division of
Gastroenterology at Mount Sinai Hospital, and the Icahn School of Medicine at Mount Sinai in New York.
 
Jeff Bornstein, M.D., Executive Medical Director, Takeda added, “The study gives physicians invaluable knowledge towards treatment decisions when starting biologic therapy. This is also the first time we have seen a direct comparison between two medicines with distinct modes of action in ulcerative colitis. This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies.”
 
The VARSITY study comprised a random selection of 769 patients, all of whom had shown an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one TNFα-antagonist other than adalimumab before being enrolled. 
 
Patients were randomly placed into one of two treatment groups - vedolizumab IV and placebo SC or adalimumab SC and placebo IV. Patients in the vedolizumab group were administered 300 mg of vedolizumab IV at weeks 0, 2, 6 and every 8 weeks after until week 46, along with placebo SC at week 0 and every 2 weeks until week 50. The adalimumab group were administered 160 mg of adalimumab SC at week 0, 80 mg at week 2 and 40 mg every 2 weeks until week 50, along with placebo IV at weeks 0, 2, 6 and every 8 weeks thereafter until week 46. Dose escalation was not permitted in either treatment arm during the study.1, 



Posted by : GoDubai Editorial Team
Viewed 2965 times
Posted on : Monday, March 11, 2019  
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of GoDubai.com.
Previous Story : A New Manufacturing Approach to Optical Transceivers
Next Story : RAK Hospital wins MRM business award for the 2nd time
Email this article Print this article

Share this article with your friends and followers
NewsVine

Comments

Back to Top  
Most Viewed Press Release posted in the last 7 days
Celebrate Mother's Day with the perfect gift from Sawalef Perfumes
The essence Guide to a Mother's Day done right!
Get Kylie Minogue's Youthful Complexation with The Organic Pharmacy's Rose Diamo...
Dubai Festival City Mall picks the perfect gifts to say thank you to all mums th...
Zoho sees over 100% market growth in the UAE, announces initiatives for the region
Visa partners with Starbucks & Hardee's to help promote the use of Apple Pay in ...
Desigual ‘Not the Same' Since 1984
Trade-in Your Old Device for a brand new Galaxy S10
Splash launches Regional Designer Collaborations
Step up your make-up game for Spring/Summer '19 with Lottie London
A major presence of the French cosmetics industry at Beauty World Middle East in...
Michael Michael Kors Spring 2019: Middle East Edit
Fit and Fabulous – now a possibility with HONOR technology
TREND ALERT: Denim | Marks & Spencer
Giti Tire Celebrates New Beginnings with Opening of First Middle East Flagship S...
Hucklebones create charming pieces for girls filled with easy-going elegance for...
HP Raises the Bar for Exciting and Secure Devices with Cutting Edge PC Innovations
Lulu Promotes Food Is Great Britain: A British Food Festival
Cole Haan Delivers True Performance Footwear With the Release of the Zerøgr...
Ericsson and UNESCO launch new global AI skill development initiative for youth
Malabar Gold & Diamonds actively participated in UAE National Sports Day conduct...
LG's Smart Kitchen Appliances Help Families Eat Healthy, Stay Fit and Waste Less
It just keeps getting better: Nokia 3.1 gets a fresh slice of Android 9 Pie
Olivia Burton presents Sunlight Florals/Mothers and daughters collection
Coach presents Park Collection
Meet HP Tango! The Home Printer Reinvented
Etisalat AGM approves Full-year 2018 dividends of 80 fils per share
Volvo Cars celebrates 60 years of sharing safety knowledge with open-for-all dig...
Epson's latest A4 business inkjets help businesses print more for less
HUGO BOSS Watches INTENSITY Collection
MOTIONGATE™ Dubai launches special treat for moms to celebrate Mother's Day on ...
Smiles, and Medals, All Round After Double Success for Team GB Siblings at World...
Jaguar F-Pace: 300 Sport and Chequered Flag Special Editions Join Award-winning...
Italian Design Day returns to Dubai with the theme Internet of Things
Fintech will radically improve financial health of people in the Gulf, say experts
New 2019 Cadillac CT6 makes its Middle East debut
IKEA X TOM DIXON X YOU
Emirates Foundation's Think Science Fair kicks off in Fujairah
Finnovex ME to focus on disruptive innovations in banking and finance sectors
Dubai Cares' latest edition of Volunteer Emirates 2019 draws support for the Nat...
The S Hotel Al Barsha to Debut at Arabian Travel Market
Saudi Arabia and Huawei sign 5 MoUs at the Saudi-Chinese Investment Forum
Applications now open for visiting students to take part in summer research at N...
Moms Eat Free on Mother's Day
Top Tips on choosing the perfect Coffee Table
Manzil and Repton school Dubai collaborate on sustainable art project
Ministry of Health launches 3rd phase of Heart Experts Programme
Team GB Cycling Star Kiera Byland Takes Gold Medal in Her First Race at World Ga...
Dubai Customs concludes 24th edition of Carpet & Art Oasis 2019
Tommy Hilfiger Two-Tone Time Collection